TICKERNERD
Menu
AMIXAMIXHealthcare · Medical Devices

AMIX Stock Forecast: Autonomix Medical, Inc. Price Predictions for 2026-2027

Last close, 10 Aug 2026
$9.29

The 2 Wall Street analysts covering Autonomix Medical, Inc. hold a median 12-month price target of $59 — +532.9% from the last close. Ticker Nerd's systematic factor model, run across ~4,600 US stocks, ranks it 13 of 100 as at 10 Aug 2026 — in the weakest quartile. The Street sees upside; the factor read is a caution. That gap is the story on this page.

Market cap
$5.0M
Ticker Nerd rank
13 / 100
Median analyst target
$59
Analysts covering
2
Ticker Nerd rank

AMIX stock analysis: one number for the whole business

Consensus tells you what everyone already believes. The model scores Autonomix Medical, Inc. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.

Where the model ranks itAs at 10 Aug 2026
13 / 100

Percentile across ~4,600 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested

Size
93
Accruals
71
Momentum
31
Growth
28
Issuance
25
Revisions
25
Volatility
10
Quality
6
Value
5

Size (93): Smaller than most of the companies we track.

Value (5): The shares cost a lot relative to the profits and assets behind them.

Wall Street

AMIX stock forecast 2026-2027: analyst price targets & predictions

The bullish and bearish analyst opinions on AMIX, reported as data — targets and ratings, the market's view beside the model's.

We don’t hold enough price history for this company yet.

What Wall Street says2 analysts
2 Buy0 Hold0 Sell
Low $42Median $59High $76

The green dot is the last close — the median target sits +532.9% from it.

Recent analyst actionsNewest first
DateFirmActionRatingTarget
17 Feb 2026Maxim GroupMaintainsBuy$5.00 → $2.00
29 Apr 2025Maxim GroupInitiatesBuy—
3 Sept 2024Ladenburg ThalmannInitiatesBuy—

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Market Radar

This page is one stock. Monday covers all of them.

Computed off the Friday close and sent before the US open.

Market Radar reports the week’s largest rank changes across roughly 4,600 US stocks, the factor behind each one, and where the market went. AMIX appears on the weeks it earns a place.

Free, every Monday. Unsubscribe any time.

Estimates

AMIX analyst estimate revisions

Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.

Which way the estimates are movingNext fiscal year
Analysts raising
1
Analysts cutting
1
Fundamentals

Autonomix Medical, Inc. (AMIX) financial data

A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.

Valuation
Trailing P/E
—
Price / sales
—
Price / book
0.8×

Cheaper than 77% of US stocks

EV / EBITDA
0.1×

Cheaper than 60% of US stocks

Growth & margins
Revenue growth (YoY)
—
Earnings growth (YoY)
—
Gross margin
—
Operating margin
0.0%

Higher than 33% of US stocks

Net margin
0.0%

Higher than 30% of US stocks

Returns & dividend
Return on equity
−238.9%

Higher than 6% of US stocks

Return on assets
−122.3%

Higher than 2% of US stocks

Dividend yield
—

Bars mark the percentile across the ~4,600 US stocks Ticker Nerd covers, among those reporting the figure.

Peers

AMIX vs competitors

The nearest names by industry and size, scored by the same model — like for like.

Its peer group, ranked by the same modelMedical Devices
CompanyMarket capTKN rank
AMIXAutonomix Medical, Inc.$5.0M
13
ICCMIceCure Medical Ltd.$9.2M
32
VNRXVolitionRX Ltd.$9.2M
26
HSCSHeartSciences, Inc.$8.1M
31
CODXCo-Diagnostics, Inc.$10.5M
29
SINTSINTX Technologies, Inc.$10.8M
25
NXLNexalin Technology, Inc.$7.5M
31

The rank is the raw material. Whether the rules would actually own Autonomix Medical, Inc. — and when they’d sell — is the membership. See the Ticker Nerd 20 →

News

Latest AMIX news & analysis

Autonomix Medical Congratulates Co-Founder & Chief Medical Officer Dr. Robert Schwartz on Receiving Prestigious 2026 Cardiovascular Tech Forum Lifetime Achievement Award

GlobeNewsWire · 10 Aug 2026positive

Autonomix Medical congratulated its co-founder and Chief Medical Officer, Dr. Robert Schwartz, on receiving the 2026 Cardiovascular Tech Forum Lifetime Achievement Award. The recognition honours him as one of the medical technology industry's most influential innovators, whose career has helped shape modern cardiovascular care.

Why it matters — The award highlights the prestige and industry recognition of one of Autonomix's key leaders, reflecting positively on the company's executive standing in medical technology.

Autonomix Stock Skyrockets After Obtaining Key Cancer Tech Patent

Benzinga · 4 Aug 2026positive

Autonomix Medical Inc. shares rose Tuesday afternoon after the company secured U.S. Patent No. 12,433,670. The headline describes the newly obtained patent as a key cancer technology patent.

Why it matters — AMIX watchers would care because securing a cancer-related patent could strengthen the company's intellectual property position in that area.

Autonomix Medical Expands Precision Neuromodulation Platform with Broad New U.S. Patent Supporting Nerve Sensing, Mapping and Targeted Therapy

GlobeNewsWire · 4 Aug 2026positive

Autonomix Medical announced the expansion of its precision neuromodulation platform with a broad new U.S. patent. The patent expands protection for technology designed to sense, map and selectively target nerves associated with tumors and cancer-related pain.

Why it matters — The new patent broadens intellectual property protection for Autonomix's core nerve-sensing and targeted-therapy technology, potentially strengthening its platform.

FAQ

Frequently asked questions about AMIX stock

What is the AMIX stock price forecast for 2026-2027?

The 2 Wall Street analysts covering Autonomix Medical, Inc. have a median 12-month price target of $59, with estimates ranging from $42 to $76. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.

Is AMIX stock a buy right now?

Of the 2 analysts covering Autonomix Medical, Inc., 2 rate it a Buy, 0 a Hold and 0 a Sell. Ticker Nerd's systematic factor model ranks Autonomix Medical, Inc. 13 out of 100 across roughly 4,600 US stocks as at 10 Aug 2026. None of this is personal advice — it does not consider your circumstances.

How does Ticker Nerd's model rank AMIX?

As at 10 Aug 2026, Autonomix Medical, Inc. ranks 13 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,600 US stocks, built from its factor families. Its strongest factor family is Size (93 of 100).

Will AMIX stock go up?

No one can know that. What the data says: the median 12-month target from 2 analysts implies +532.9% from the last close, and Ticker Nerd's factor model ranks Autonomix Medical, Inc. 13 out of 100 as at 10 Aug 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.

What is the AMIX stock forecast for 2030?

No analyst covering Autonomix Medical, Inc. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for AMIX are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $42 to $76 over the next 12 months.

What does Autonomix Medical, Inc. do?

Autonomix Medical Inc. is a medical device company developing precision nerve-targeted therapies to treat diseases involving the peripheral nervous system.

What is the latest news on AMIX?

The most recent item we track (GlobeNewsWire, 10 Aug 2026): "Autonomix Medical Congratulates Co-Founder & Chief Medical Officer Dr. Robert Schwartz on Receiving Prestigious 2026 Cardiovascular Tech Forum Lifetime Achievement Award". Autonomix Medical congratulated its co-founder and Chief Medical Officer, Dr. Robert Schwartz, on receiving the 2026 Cardiovascular Tech Forum Lifetime Achievement Award. The recognition honours him as one of the medical technology industry's most influential innovators, whose career has helped shape modern cardiovascular care.

Company

About Autonomix Medical, Inc.

Autonomix Medical Inc. is a medical device company developing precision nerve-targeted therapies to treat diseases involving the peripheral nervous system. Its first-in-class platform technology features a proprietary catheter-based microchip sensing array that detects and differentiates neural signals with ultra-high sensitivity and on-site data processing, surpassing existing technologies. This enables real-time identification of target nerves, followed by proprietary radio frequency ablation to precisely disable them, and verification of treatment efficacy in a minimally invasive transvascular procedure. Initially focused on pain management for pancreatic cancer patients, the platform addresses unmet needs in chronic pain by offering targeted denervation as an alternative to opioids or invasive methods. With potential applications across cardiology, hypertension, pulmonology, gastroenterology, and interventional pain management, Autonomix Medical Inc. equips physicians with innovative tools for accurate diagnosis and therapy. Headquartered in The Woodlands, Texas, the company advances this breakthrough system protected by a global intellectual property portfolio.

CEO Mr. Bradley Hauser · 8 employees · United States · https://autonomix.com